<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parry, Nicola</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">De Ferrari, Gaetano M.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Favorable Phase 2 Data for Ranolazine in AF</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">24-25</style></pages><abstract><style  face="normal" font="default" size="100%">This article presents results of the Ranolazine in Atrial Fibrillation Following an Electrical Cardioversion randomized trial [RAFFAELLO; NCT01534962], an international, double-blind, parallel, Phase 2, dose-ranging study testing three oral ranolazine doses. The results demonstrated safety and provided favorable findings with regard to efficacy for patients with atrial fibrillation.</style></abstract><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>